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http://www.biomedcentral.com/1756-0500/7/815RESEARCH ARTICLE Open AccessContribution of syndecan-4 genetic variants to
hypertension, the TAMRISK study
Tarja Kunnas and Seppo T Nikkari*Abstract
Background: A human syndecan-4 genetic variant (rs1981429) has previously been associated with lean tissue mass
and intra-abdominal fat, and SNP rs4599 with resting energy expenditure in healthy early pubertal children. These
variations could thus cause overweight and hypothetically lead to hypertension. Their association with body mass
index and blood pressure was therefore studied in a Finnish cohort of adults.
Methods: The data was collected from the Tampere adult population cardiovascular risk study (TAMRISK). A total of
279 cases with hypertension and/or coronary artery disease (CAD), and 488 non-hypertensive healthy controls were
selected from a Finnish periodic health examination 50-year-old cohort. Information was available also from their
45-year examination. DNA was extracted from buccal swabs and human syndecan-4 gene SNPs were analyzed
using KASP genotyping.
Results: The SNP rs1981429 variant TT was significantly associated with hypertension, as compared to variants TG and
GG at the age of 50 years (p=0.015). The variant TT was also associated with increased BMI at the ages of 45 and 50 years
(p=0.008 and p=0.026, respectively). In addition, TT genotype associated with increased CAD prevalence (P=0.013). No
significant associations between rs4599 variants and hypertension or BMI were found. In haplotype analysis the number
of alleles T (rs1981429)/C (rs4599) was linearly associated with CAD prevalence; the highest prevalence (13%) was in
haplotype TT/CC and lowest prevalence (1%) in haplotype GG/TT (p=0.01).
Conclusion: Syndecan-4 polymorphisms were associated with essential hypertension, BMI, and CAD prevalence in the
TAMRISK study.Background
There are four syndecans in mammals [1]. Syndecans are
cell surface proteoglycans with heparan sulfate chains that
bind to other ECM components, growth factors, clotting
factors, and even to enzymes involved in lipid metabolism
[2]. Syndecan-4 is widely expressed in mesodermal tissues,
including the heart and vasculature [3]. It has also been
suggested that modification of LDL triggers an increased
uptake by macrophages through a syndecan-4-dependent
pathway leading to foam cell formation [4]. Syndecan-4 is
upregulated in the hypertrophic left ventricle following
myocardial infarction, suggesting a role for this proteogly-
can family in cardiac remodeling [5]. In fact, experimental
data has suggested that syndecan-4 plays an important role
in the immune response of the heart to increased pressure,
influencing cardiac remodeling [6].* Correspondence: seppo.nikkari@uta.fi
Department of Medical Biochemistry, University of Tampere Medical School
and Fimlab laboratories, Tampere 33014, Finland
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article, unless otherwise stated.Single nucleotide polymorphisms (SNPs) in the human
syndecan-4 gene have previously been tested for association
with body composition, metabolism, glucose homeostasis,
and sleep traits in a cohort of healthy early pubertal chil-
dren [7]. SNP rs4599 was significantly associated with rest-
ing energy expenditure, fasting glucose levels and sleep
duration. On average, children homozygous for the minor
allele C had lower levels of glucose, higher resting energy
expenditure, and slept shorter than children homozygous
for the common allele T. SNP rs1981429 was associated
with lean tissue mass and intra-abdominal fat. These previ-
ous results suggest that syndecan family members play a
key role in the regulation of body metabolism.
Lifestyle factors are the major causes of hypertension in
Western countries, including overweight, physical inactivity,
high salt intake and low potassium intake [8]. The genetic
component in hypertension is estimated as 30 – 50% of the
total impact [9]. On the other hand, although candidate-
gene and genome-wide association studies (GWAS) haveentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ated with blood pressure, collectively these explain only a
few percent of the heritability for hypertension [10,11].
To our knowledge, there are no previous studies that
have addressed the association of syndecan-4 genetic vari-
ants with hypertension. We wanted to assess the role of
syndecan-4 variants in a Finnish population, by analyzing
cohorts from the Tampere adult population cardiovascular
risk study (TAMRISK) [12].
Methods
Subjects
The data for the TAMRISK study was collected from peri-
odic health examinations (PHE) done for 50-year-old men
and women living in Tampere, Finland [12]. TAMRISK data
includes information of risk factors for hypertension: blood
pressure, weight, family history of cardiovascular diseases,
lipid values and smoking, diabetes and exercise habits.
Buccal swabs for DNA extraction and a permissions form
to use PHE data were collected by mail subsequent to the
physical examination. The DNA samples were collected
during years 2006–2010. Informed consent was obtained
from all participants. The Ethics Committees of the Tampere
University Hospital and the City of Tampere approved the
study.
Cases (n=279) in this study were the subjects who had
hypertension and/or CAD at the age of 50 years (as diag-
nosed by a physician) and for each case, at least one normo-
tensive control (n=448) with the same sex and similar
smoking habits, were chosen from a PHE cohort (n=6000).
Smoking status was evaluated based on self-reporting.
Finally, we selected a subpopulation of men and women
who had available data of blood pressure measurements at
the age of 45- and 50 years.
Baseline measurements
The basic evaluation in 1988–91 included an interview by a
public health nurse. The interview was conducted using a
structured questionnaire about health and health-related
behaviour, including questions about current and previous
diseases. Information on current and previous diseases was
based on self-report of diagnosis by a physician, including
history of coronary artery disease, myocardial infarction and
diabetes. Family history of hypertension in a close relative
was also asked in the questionnaire. The frequency of phys-
ical exercise comprised both leisure and commute related ac-
tivity. Physical examination included a single blood pressure
(BP) measurement (mm of mercury) using a calibrated mer-
cury sphygmomanometer. Height (cm) and weight (kg) were
recorded from which the body mass index was calculated.
Genotyping
DNA was extracted from buccal swabs using a commer-
cial kit (Qiagen Inc., Valencia, Calif., USA). The sampleswere transferred into 96-well plates and genotyped for
SDC4 SNPs rs4599 and rs1981429 at LGC Genomics
(Herz, UK) using the Competitive Allele Specific PCR
(KASP) technique.
Statistical analysis
Associations of the two genotyped SNPs with risk factors
were analyzed using dominant, additive, and recessive
models. We used dummy variables to code the three geno-
types in each model [7]. In the additive model, we used 0, 1
and 2 to code for individuals homozygous for the major
allele, heterozygous, and homozygous for the minor allele,
respectively. In the dominant model for rs4599, genotypes
T/T, T/C, C/C were coded as 0, 1, 1, respectively; in the re-
cessive model, genotypes T/T, T/C, C/C were coded as 0, 0,
1, respectively. In the dominant model for rs1981429, geno-
types T/T, T/G, G/G were coded as 0, 1, 1, respectively; in
the recessive model, genotypes T/T, T/G, G/G were coded
as 0, 0, 1, respectively.
Analysis of variance, t-test, and Chi-square test for cat-
egorical variables were applied for the comparison of geno-
types. To find the interpretative factors for hypertension/
CAD, we used logistic regression analysis. If the distribution
was skewed, the analysis was performed using transformed
values to approximately normalize the distribution. P values
less than 0.05 were considered significant. Analyses were
carried out using SPSS 16.0 for Windows (SPSS Inc.,
Chicago, Illinois, USA).
Results
Clinical characteristics of the cases (279) and controls (488)
at the age of 50 years are presented in Table 1. The case
group of subjects with hypertension and/or CAD was com-
pared to healthy controls. Cases had higher body mass
index (BMI) (p<0.001), fasting glucose (p<0.001), systolic
blood pressure (p<0.001) and diastolic blood pressure
(p<0.001) compared to controls. In the whole study popula-
tion the frequencies of the rs1981429 variants were 0.240
for GG (n=190), 0.514 for TG (n=399) and 0.245 (n=190)
for TT. The frequencies of the rs1981429 variants were sig-
nificantly different between cases and controls. In the whole
study population the frequencies of the rs4599 variants
were 0.038 for CC (n=32), 0.369 for TC (n=285) and 0.593
(n=462) for TT. These frequencies did not differ between
cases and controls (Table 1).
For further analyses, the case and control groups were
combined (Table 2). Significant associations with hyperten-
sion were found in the dominant model, comparing
rs1981429 variant TT to the G allele carriers at the age of
50 years (p=0.015). Individuals homozygous for the T allele
had 0.8 mmHg and 2.3 mmHg higher diastolic blood pres-
sure at the age of 45 compared to genotypes GG and TG,
respectively (p=0.025). At the age of 45 years, 9% of the
combined groups were on blood pressure medication,
Table 1 Clinical characteristics of study population at the age of 50 years
Cases (n = 279) Controls (n = 488) P
Age (years) 50 ± 0 50 ± 0
Gender (male) % 64 62 0.699
Body mass index (kg/m2) 28.8 ± 5.2 25.9 ± 4.0 <0.000
Cholesterol (mmol/l) 5.41 ± 1.08 5.39 ± 0.88 0.769
Glucose (mmol/l) 5.24 ± 1.40 4.85 ± 0.52 <0.000
Systolic blood pressure (mm Hg) 142.4 ± 16.4 131.3 ± 15.9 <0.000
Diastolic blood pressure (mm Hg) 92.3 ± 8.6 85.8 ± 9.8 <0.000
Exercise (at least twice a week) % 36.0 30.0 0.090
Diabetes % 8.0 0 <0.000
Myocardial infarction % 6.0 0 <0.000
Coronary artery disease % 11.0 0 <0.000
Syndecan-4 rs4599 (CC/TC/TT) % 4.4/36.1/59.5 3.3/37.6/59.1 0.717
Syndecan-4 rs1981429 (GG/TG/TT) % 22.4/48.0/29.6 25.4/53.3/21.3 0.017
Values are means ± SD.
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was associated with increased BMI at the ages of 45 and
50 years (p=0.008 and p=0.026, respectively). Individuals
homozygous for the T allele had 2% and 3% higher BMI
at the ages of 45 and 50 years than those homozygous
for the G allele, respectively. All of the above findingsTable 2 Means (SD) for hypertension, coronary artery disease
syndecan-4 polymorphisms
rs4599 C/C T/C
n 32 287
Hypertension % 39 31
Coronary artery disease % (n=31) 10 5
Systolic blood pressure (mm Hg) at 45 133.6 (15.3) 132.2 (13.5)
Systolic blood pressure (mm Hg) at 50 136.8 (12.7) 134.7 (16.7)
Diastolic blood pressure (mm Hg) at 45 83.6 (7.5) 85.1 (9.0)
Diastolic blood pressure (mm Hg) at 50 87.3 (8.4) 88.0 (10.1)
Body mass index (kg/m2) at 45 27.4 (4.5) 26.5 (4.3)
Body mass index (kg/m2) at 50 27.6 (4.5) 26.9 (4.7)
rs1981429 G/G T/G
n 185 396
Hypertension % 32 32
Coronary artery disease % (n=31) 2 3
Systolic blood pressure (mm Hg) at 45 133.6 (15.7) 131.5 (13.7)
Systolic blood pressure (mm Hg) at 50 133.1 (16.7) 135.4 (17.3)
Diastolic blood pressure (mm Hg) at 45 85.9 (10.0) 84.4 (8.8)
Diastolic blood pressure (mm Hg) at 50 87.1 (9.6) 88.4 (10.1)
Body mass index (kg/m2) at 45 26.4 (4.0) 26.1 (4.0)
Body mass index (kg/m2) at 50 27.1 (4.5) 26.6 (4.4)
*indicate P values calculated assuming additive, dominant, and recessive models. Pand significant differences were also observed when
analyzing the data in the additive model (Table 2).
The rs1981429 variant TT was also associated with in-
creased CAD prevalence (P=0.010). Individuals homozy-
gous for the T allele had 71% more CAD than those
homozygous for the G allele. In logistic regression the, blood pressure and body mass index according to
P*
T/T Additive Dominant (TT) Recessive (CC)
448
35 0.496 0.225 0.334
3 0.057 0.061 0.108
133.0 (14.3) 0.735 0.542 0.750
135.3 (17.1) 0.771 0.738 0.485
85.6 (9.5) 0.471 0.329 0.330
88.1 (9.7) 0.904 0.780 0.640
26.3 (4.2) 0.368 0.368 0.215
26.9 (4.7) 0.776 0.776 0.438
T/T Additive Dominant (TT) Recessive (GG)
186
41 0.074 0.015 0.283
7 0.013 0.010 0.056
134.2 (14.2) 0.086 0.108 0.379
136.2 (15.9) 0.157 0.252 0.064
86.7 (9.4) 0.018 0.025 0.408
87.9 (9.2) 0.330 0.928 0.161
27.2 (4.7) 0.024 0.008 0.832
27.6 (5.2) 0.038 0.026 0.629
values <0.05 are highlighted in bold case.
Figure 1 Association of the most common syndecan-4 haplotypes
with coronary artery disease (CAD) prevalence.
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(p=0.009, CI 1.3 – 5.4) of CAD compared to the G allele
carriers. The results remained the same (2.5 fold risk)
after adjusting with BMI and gender.
No significant association of the rs4599 variant with
hypertension, blood pressure or BMI was found. However,
there was a nonsignificant trend for association of the
C-allele with CAD. The haplotype frequencies for SNPs
rs1981429/rs4599 are shown in Table 3. In haplotype ana-
lysis of the most common haplotypes (with more than 20
subjects each), the number of alleles T (rs1981429)/C (rs
4599) was linearly associated with CAD prevalence; the
highest prevalence (13%) was in haplotype TT/CC and low-
est prevalence (1%) in haplotype GG/TT (p=0.01) (Figure 1).
In logistic regression the risk for CAD was 8.6 fold higher
(p=0.01, CI 1.6 – 45.7) in haplotype TT/CC compared to
GG/TT.Discussion
We report that syndecan-4 gene SNP rs1981429 variant
TT was significantly associated with hypertension, as com-
pared to variants TG and GG at the age of 50 years. To our
knowledge, there are no previous studies showing such an
association. There was also an association of this genotype
with diastolic blood pressure at the age of 45 years. The ob-
served effect of a single gene variation on blood pressure in
GWAS studies is low: +1.16 mmHg at the highest [10], as
also seen in the present study. Individuals homozygous for
the T allele had 0.8 mmHg and 2.3 mmHg higher diastolic
blood pressure at the age of 45 compared to genotypes GG
and TG, respectively. A possible difference in blood pres-
sure at the age of 50 might be difficult to establish, since
practically all of the subjects who had hypertension were
on blood pressure medication at this age.
There were only 31 subjects with CAD, but SNP
rs1981429 variant TT was associated with increased CAD
prevalence. Furthermore, in haplotype analysis the number
of alleles T (rs1981429)/C (rs 4599) was linearly associatedTable 3 All haplotypes for SNPs rs1981429/rs4599
Frequency Percent
GG/CC 1 0.1
TG/CC 5 0.7
TT/CC 23 3.0
GG/TC 11 1.4
TG/TC 173 22.6
TT/TC 101 13.2
GG/TT 171 22.3
TG/TT 220 28.7
TT/TT 62 8.1
Total 767 100.0with CAD prevalence; the highest prevalence was in haplo-
type TT/CC and lowest prevalence in GG/TT.
Our findings of the association between syndecan-4
SNP rs1981429 with hypertension and CAD are interest-
ing, because serum syndecan-4 concentration has shown
promise as a novel diagnostic and prognostic biomarker
for heart failure. Serum syndecan-4 has been suggested
to represent a biomarker of pathological left ventricle re-
modeling [5,13-15]. Syndecan-4 levels are increased in
the hypertrophic myocardium of patients with aortic
stenosis [14], and increased syndecan-4 levels have also
been demonstrated in the post-infarcted heart [5,16]. In
cardiac cells, syndecan-4 is localized to cellular adhesion
sites which are important for signaling across the mem-
brane [1,17].
The variant TT of rs1981429 was also associated with in-
creased BMI at the ages of 45 and 50 years. This is in line
with previous findings by De Luca et al. that SNPs in the
human syndecan-4 gene were associated with body com-
position in a cohort of healthy early pubertal children [7].
However in the previous study, the variant GG of SNP
rs1981429 was associated with increased intra-abdominal
fat and less lean mass, while we report an association of the
variant TT with BMI. On the other hand, the previous
study population was smaller (n=252), and represented a
mixture of healthy early pubertal children with African
American, Caucasian and Hispanic ancestry, while our
study population (n=767) represented Caucasian adults.
Nevertheless, these previous and our present results suggest
that syndecan family members may play a role in the regu-
lation of body metabolism.
Syndecan-4 is essential in skeletal muscle development
and regeneration [18] and plays a role in the regulation
of focal adhesion kinase phosphorylation [19], which in
turn mediates the insulin sensitivity of skeletal muscle
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it is plausible that syndecan-4 is involved in energy regula-
tion via an insulin-signaling mechanism that impacts overall
body metabolism [7]. The mechanisms behind associations
of syndecan-4 polymorphisms with essential hypertension,
BMI, and CAD need further studies.
Conclusions
In conclusion, syndecan-4 polymorphisms were associ-
ated with essential hypertension, BMI, and CAD preva-
lence in the TAMRISK study.
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